Published 20 April 2018 Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens. Helperby also presented preclinical data which shows that AZT is active … [Read more...]
Shire rejects $63bn takeover proposal from Takeda
PBR Staff Writer Published 20 April 2018 Ireland-based Shire has rejected a $63bn acquisition offer from Takeda Pharmaceutical, saying that it undervalues the company, its growth prospects and pipeline. The rare disease drug maker revealed that the Japanese pharma company made three offers recently. Takeda’s latest offer came on 13 April, which was £46.50 per each … [Read more...]
BenevolentAI raises $115m to advance AI-enabled drug development activities
PBR Staff Writer Published 19 April 2018 BenevolentAI has secured $115m funding to advance drug development activities and extend its artificial intelligence (AI) platform capabilities. The company has raised the funding from new and existing investors at a pre-money valuation of $2bn in the financing round of the AI pharmaceutical sector. From 2013, BenevolentAI has … [Read more...]
FDA approves Tagrisso as first-line treatment for EGFR-mutated non-small cell lung cancer
Published 19 April 2018 The US Food and Drug Administration (FDA) has approved AstraZeneca’s Tagrisso (osimertinib) as the first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial, which were presented at the … [Read more...]
Advent in talks to buy Sanofi’s European generics business for EUR1.9bn
PBR Staff Writer Published 18 April 2018 US-based global private equity firm Advent International has entered into exclusive talks to acquire Sanofi’s European generics business, Zentiva, for €1.9bn. Sanofi, which had fully acquired Zentiva in a deal worth about €1.8bn in 2009, is looking to sell it after considering the European generics business to be … [Read more...]